Choreo LLC Increases Stock Position in Gilead Sciences, Inc. $GILD

Choreo LLC grew its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 1.1% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 47,852 shares of the biopharmaceutical company’s stock after purchasing an additional 498 shares during the quarter. Choreo LLC’s holdings in Gilead Sciences were worth $5,305,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also made changes to their positions in the company. One Wealth Advisors LLC grew its position in Gilead Sciences by 34.8% during the 2nd quarter. One Wealth Advisors LLC now owns 9,163 shares of the biopharmaceutical company’s stock worth $1,016,000 after purchasing an additional 2,364 shares during the last quarter. Ariel Investments LLC raised its holdings in shares of Gilead Sciences by 7.7% in the first quarter. Ariel Investments LLC now owns 430,424 shares of the biopharmaceutical company’s stock valued at $48,229,000 after buying an additional 30,630 shares during the last quarter. Sivik Global Healthcare LLC boosted its stake in shares of Gilead Sciences by 25.0% during the second quarter. Sivik Global Healthcare LLC now owns 50,000 shares of the biopharmaceutical company’s stock worth $5,544,000 after buying an additional 10,000 shares during the period. Simplify Asset Management Inc. grew its holdings in shares of Gilead Sciences by 148.6% during the second quarter. Simplify Asset Management Inc. now owns 52,890 shares of the biopharmaceutical company’s stock worth $5,864,000 after buying an additional 31,618 shares during the last quarter. Finally, VeraBank N.A. acquired a new position in Gilead Sciences in the 2nd quarter valued at about $397,000. 83.67% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Gilead Sciences

In other news, CEO Daniel Patrick O’day sold 10,000 shares of the business’s stock in a transaction that occurred on Tuesday, October 28th. The stock was sold at an average price of $119.39, for a total transaction of $1,193,900.00. Following the sale, the chief executive officer owned 581,203 shares of the company’s stock, valued at $69,389,826.17. The trade was a 1.69% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Deborah H. Telman sold 53,646 shares of the company’s stock in a transaction that occurred on Wednesday, November 12th. The stock was sold at an average price of $122.85, for a total value of $6,590,411.10. Following the completion of the sale, the executive vice president owned 43,676 shares in the company, valued at approximately $5,365,596.60. This represents a 55.12% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 115,146 shares of company stock valued at $14,012,141 in the last 90 days. Insiders own 0.27% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on GILD shares. Argus increased their price objective on Gilead Sciences from $130.00 to $135.00 and gave the stock a “buy” rating in a research report on Tuesday, November 4th. Rothschild & Co Redburn increased their price target on Gilead Sciences from $143.00 to $153.00 in a report on Monday, November 10th. Wolfe Research lifted their price objective on shares of Gilead Sciences from $135.00 to $140.00 and gave the company an “outperform” rating in a research report on Thursday, October 23rd. Sanford C. Bernstein reissued an “outperform” rating on shares of Gilead Sciences in a research note on Monday, November 3rd. Finally, Royal Bank Of Canada raised their target price on shares of Gilead Sciences from $100.00 to $105.00 and gave the stock a “sector perform” rating in a research note on Friday, October 31st. Two investment analysts have rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $130.65.

Gilead Sciences Price Performance

Gilead Sciences stock opened at $127.51 on Thursday. The company has a market cap of $158.20 billion, a P/E ratio of 25.40, a price-to-earnings-growth ratio of 0.81 and a beta of 0.32. Gilead Sciences, Inc. has a one year low of $88.57 and a one year high of $128.70. The business has a fifty day moving average of $119.36 and a two-hundred day moving average of $114.25. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.15 and a current ratio of 1.32.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share for the quarter, topping analysts’ consensus estimates of $2.16 by $0.31. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The business had revenue of $7.77 billion for the quarter, compared to analysts’ expectations of $7.42 billion. During the same period in the prior year, the company posted $2.02 EPS. The business’s revenue for the quarter was up 3.0% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. As a group, analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 30th. Shareholders of record on Monday, December 15th will be issued a $0.79 dividend. The ex-dividend date of this dividend is Monday, December 15th. This represents a $3.16 dividend on an annualized basis and a yield of 2.5%. Gilead Sciences’s dividend payout ratio (DPR) is 48.99%.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.